Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Consulting agrmnt
Director departure
Quarterly results
APPLIED DNA SCIENCES INC (APDN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "STONY BROOK, N.Y. - -"
08/01/2023 8-K Quarterly results
07/13/2023 8-K Investor presentation
Docs: "CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.",
"Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT TM Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach",
"Applied DNA Sciences, Inc. Applied DNA Acquires Spindle Biotech Better RNA....Faster July 13, 2023"
05/11/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "STONY BROOK, N.Y."
05/05/2023 8-K Other Events  Interactive Data
03/27/2023 8-K Quarterly results
02/28/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "LEASE AGREEMENT",
"LEASE AGREEMENT"
02/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "STONY BROOK, N.Y. – -"
12/14/2022 8-K Quarterly results
09/23/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/11/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
08/02/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Forward-Looking Statements"
07/28/2022 8-K Quarterly results
07/27/2022 8-K Investor presentation
Docs: "Applied DNA Sciences, Inc. The Future of RNA Therapies Produced with LinearDNA"
05/12/2022 8-K Quarterly results
02/22/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "PRE-FUNDED COMMON STOCK PURCHASE WARRANT applied dna sciences, inc. Warrant Shares:_______ Initial Exercise Date: February__, 2022 THIS PRE-FUNDEDCOMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. until this Warrant is exercised in full] but not thereafter, to subscribe for and purchase from Applied DNA Sciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .       &...",
"COMMON STOCK PURCHASE WARRANT applied dna sciences, inc. Warrant Shares: _______ Issue Date: February __, 2022 Initial Exercise Date: August ___, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after August __, 2022 and on or prior to 5:00 p.m. on ________ 1 but not thereafter, to subscribe for and purchase from DNA Applied Sciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .         &#82...",
"Letter re: Registered Direct Public Offering",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 21, 2022, between Applied DNA Sciences, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATIO...",
"PLACEMENT AGENCY AGREEMENT",
"Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering"
02/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Financial Tables Follow APPLIED DNA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS December 31, September 30, 2021 2021 ASSETS Current assets: Cash and cash equivalents $ 2,748,368 $ 6,554,948 Accounts receivable, net of allowance of $39,821 and $29,821 at December 31 ,2021 and September 30, 2021, respectively 3,857,275 2,804,039 Inventories 1,300,629 1,369,933 Prepaid expenses and other current assets 593,149 568,881 Total current assets 8,499,421 11,297,801 Property and equipment, net 2,807,852 3,023,915 Deposits 95,040 95,040 Total Assets $ 11,402,313 $ 14,416,756 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued liabilities $ 2,521,353 $ 2,991,343 Deferred revenue 457,538 281,000 Total current liabilities 2,978,891 3,272,343 Long term accrued liabilities 31..."
12/09/2021 8-K Quarterly results
11/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/17/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
Docs: "Financial Tables Follow APPLIED DNA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, September 30, 2021 2020 ASSETS Current assets: Cash and cash equivalents $ 12,173,443 $ 7,786,743 Accounts receivable, net of allowance of $7,438 and $11,968 at June 30, 2021 and September 30, 2020, respectively 737,347 194,319 Inventories 429,116 497,367 Prepaid expenses and other current assets 356,414 599,296 Total current assets 13,696,320 9,077,725 Property and equipment, net 2,576,616 1,277,655 Other assets: Deposits 95,053 95,083 Goodwill 285,386 285,386 Intangible assets, net 536,354 605,330 Total Assets $ 17,189,729 $ 11,341,179 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued liabilities $ 1,321,753 $ 1,926,427 Promissory notes payable-current portion - 329,29..."
05/13/2021 8-K Quarterly results
04/01/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "STONY BROOK, N.Y. - January 20, 2021 -"
01/13/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/17/2020 8-K Quarterly results
Docs: "Applied DNA Reports 2020 Year End and Fiscal Fourth Quarter Financial Results"
10/20/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/14/2020 8-K Quarterly results
10/08/2020 8-K Quarterly results
09/29/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy